JO3383B1 - مثبطات cdc7 - Google Patents

مثبطات cdc7

Info

Publication number
JO3383B1
JO3383B1 JOP/2014/0067A JOP20140067A JO3383B1 JO 3383 B1 JO3383 B1 JO 3383B1 JO P20140067 A JOP20140067 A JO P20140067A JO 3383 B1 JO3383 B1 JO 3383B1
Authority
JO
Jordan
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
useful
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0067A
Other languages
English (en)
Inventor
Andrew Woods Timothy
Dean Dally Robert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3383B1 publication Critical patent/JO3383B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات أيزوإندولينون، أو ملح مقبول صيدليًا منها، والتي تثبِّط CDC7، وبالتالي يمكن أن تكون مفيدة في علاج السرطان.
JOP/2014/0067A 2013-03-14 2014-03-04 مثبطات cdc7 JO3383B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JO3383B1 true JO3383B1 (ar) 2019-03-13

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0067A JO3383B1 (ar) 2013-03-14 2014-03-04 مثبطات cdc7

Country Status (37)

Country Link
US (1) US9156824B2 (ar)
EP (1) EP2970221B1 (ar)
JP (1) JP6064079B2 (ar)
KR (1) KR101718645B1 (ar)
CN (1) CN105008351B (ar)
AP (1) AP2015008734A0 (ar)
AU (1) AU2014228374B2 (ar)
BR (1) BR112015020466B1 (ar)
CA (1) CA2900773C (ar)
CL (1) CL2015002530A1 (ar)
CR (1) CR20150416A (ar)
CY (1) CY1119199T1 (ar)
DK (1) DK2970221T3 (ar)
EA (1) EA027012B1 (ar)
ES (1) ES2639793T3 (ar)
GT (1) GT201500263A (ar)
HK (1) HK1212696A1 (ar)
HR (1) HRP20171151T1 (ar)
HU (1) HUE033482T2 (ar)
IL (1) IL240962B (ar)
JO (1) JO3383B1 (ar)
LT (1) LT2970221T (ar)
ME (1) ME02805B (ar)
MX (1) MX363438B (ar)
MY (1) MY188145A (ar)
NZ (1) NZ710392A (ar)
PE (1) PE20151654A1 (ar)
PH (1) PH12015502091A1 (ar)
PL (1) PL2970221T3 (ar)
PT (1) PT2970221T (ar)
RS (1) RS56122B1 (ar)
SG (1) SG11201507541PA (ar)
SI (1) SI2970221T1 (ar)
TN (1) TN2015000349A1 (ar)
TW (1) TWI622396B (ar)
UA (1) UA116125C2 (ar)
WO (1) WO2014143601A1 (ar)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2906555T3 (en) * 2012-10-15 2017-02-06 Pfizer Ireland Pharmaceuticals Process for the preparation of voriconazole and analogs thereof
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
BR122019024759B1 (pt) 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
SG11201507382QA (en) 2013-03-14 2015-10-29 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
EP3511331A1 (en) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CA3037605A1 (en) * 2016-09-22 2018-03-29 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
WO2020212434A1 (en) * 2019-04-16 2020-10-22 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
PE20151654A1 (es) 2015-11-12
DK2970221T3 (en) 2017-07-31
TW201521726A (zh) 2015-06-16
GT201500263A (es) 2016-03-02
ME02805B (me) 2018-01-20
CA2900773C (en) 2018-04-17
BR112015020466A2 (pt) 2017-07-18
US20140275121A1 (en) 2014-09-18
TWI622396B (zh) 2018-05-01
PH12015502091B1 (en) 2016-01-18
LT2970221T (lt) 2017-09-11
CY1119199T1 (el) 2018-02-14
MX2015012583A (es) 2016-01-20
HK1212696A1 (zh) 2016-06-17
IL240962B (en) 2020-04-30
CL2015002530A1 (es) 2016-03-28
MX363438B (es) 2019-03-22
CN105008351A (zh) 2015-10-28
CR20150416A (es) 2015-09-16
NZ710392A (en) 2020-05-29
EP2970221B1 (en) 2017-06-28
KR101718645B1 (ko) 2017-03-21
JP6064079B2 (ja) 2017-01-18
EA201591509A1 (ru) 2015-12-30
SG11201507541PA (en) 2015-10-29
HUE033482T2 (en) 2017-12-28
JP2016512498A (ja) 2016-04-28
US9156824B2 (en) 2015-10-13
HRP20171151T1 (hr) 2017-10-06
BR112015020466A8 (pt) 2019-11-12
UA116125C2 (uk) 2018-02-12
KR20150119101A (ko) 2015-10-23
PT2970221T (pt) 2017-09-22
EA027012B1 (ru) 2017-06-30
PH12015502091A1 (en) 2016-01-18
BR112015020466B1 (pt) 2022-07-26
WO2014143601A1 (en) 2014-09-18
AP2015008734A0 (en) 2015-09-30
CA2900773A1 (en) 2014-09-18
IL240962A0 (en) 2015-11-30
AU2014228374A1 (en) 2015-08-06
AU2014228374B2 (en) 2016-09-01
MY188145A (en) 2021-11-23
CN105008351B (zh) 2017-03-15
RS56122B1 (sr) 2017-10-31
PL2970221T3 (pl) 2017-11-30
EP2970221A1 (en) 2016-01-20
TN2015000349A1 (en) 2017-01-03
SI2970221T1 (sl) 2017-08-31
ES2639793T3 (es) 2017-10-30

Similar Documents

Publication Publication Date Title
PH12015502091A1 (en) Cdc7 inhibitors
HK1249524A1 (zh) 用於治療血載癌症的免疫檢查點抑制劑
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2016001963A (es) Metodo de seleccion.
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
PH12017500881B1 (en) Aurora a kinase inhibitor
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EP3362066A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3664803A4 (en) DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX2015013021A (es) 5-bromo-indirrubinas.
GB201702160D0 (en) Inhibitors for use in therapy
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
EP3025711A4 (en) Medicine for preventing or treating hypertension
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
EP3131550A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
UA88729U (uk) Спосіб консервативного лікування хронічного геморою
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.